From April 22 to 25, Seegene participated in ECCMID 2017 (ECCMID: European Congress of Clinical Microbiology and Infectious Diseases), which was held in Vienna, Austria this year. At the congress, Seegene presented the new concept called ‘All MDx Assays in One Platform’, which means that diverse molecular diagnostics test can be performed in one platform. Also, through the Seegene Integrated Symposium at ECCMID 2017, clinical utility and performance of Seegene’s Allplex™ products for respiratory, gastrointestinal and sexually transmitted infections were verified, receiving a lot of attention from clinical practitioners from all over the Europe.

ECCMID, the biggest congress in Europe on infectious diseases, infection controls and clinical microbiology is held every year, and the world’s leading experts join this congress to present and discuss the latest results. Over 12,400 participants from 127 countries attended this congress this year.

With the concept of 'Seegene’s One Platform’ solution in which almost every molecular diagnostics assays can be done with single platform, this year Seegene offered on-site demonstrations of Allplex™ Respiratory Panel Assays, Allplex™ Gastrointestinal Panel Assays, Allplex™ STI Assays, etc., and these demonstrations were very well-received by the congress participants.

Especially as Seegene’s product portfolio covering various disease areas is expected to be expanded through Seegene’s ‘Project 100’, many commercial laboratories and hospitals in France, Spain, the UK, etc. requested for assay evaluations with the purpose to launch Seegene products in their institutes.

In addition to on-site demonstrations, Seegene has held the Seegene Integrated Symposium at ECCMID for four straight years, and this year the data on clinical utility and performance of Allplex™ products were presented by the world-renowned experts in infectious diseases.

In the Seegene Integrated Symposium entitled “Multiplex Molecular Diagnostics for Infectious Diseases: Innovation and Value Discovery”, 4 speakers were invited. Firstly, Prof. Hubert M. Niesters (the Netherlands) highlighted the need for incorporating molecular diagnostics into routine testing and also for implementing well validated assays. Then Prof. Tomas Pumarola Sune (Spain) presented the data on clinical impact of multiplex assays in diagnosis of gastrointestinal infections. The next speaker was Dr. Jari Hirvonen from Finland, and he spoke about the clinical data showing the clinical utility and high performance of Allplex™ Respiratory Panel Assays. Dr. Carsten Tiemann was the last speaker, and the main point of his presentation was that Seegene’s STI assays are beneficial for the detection of “unknowns” and should become an important tool for screening programs. He also commented that Seegene’s STI assays are time- and cost efficient, sensitive and reliable.

With approximately 500 participants in this symposium, Prof. Bruno Lina (France) who was the chairperson in this syposium and who is the world-renowned expert in respiratory virus diseases moderated the discussion and Q&A session between 4 speakers and the participants. Based on the survey conducted of the symposium attendees, approximately 35 percent of the respondents provided positive feedback on launching Seegene assays in their institutes, and it proves the great potential of Allplex products to be successfully launched in the market worldwide.

A Seegene spokesperson said, “By revealing our ‘One Platform’ solution and our new product portfolio through ‘Project 100’ at ECCMID 2017, we discovered a very wide pool of potential customers. Also, through the Seegene Integrated Symposium in which clinical utility and performance of the Allplex™ products currently available in the market were validated, we were able to greatly enhance the credibility and awareness of our products. Once automated assay development becomes feasible, we expect the launching of Allplex™ products in the new markets will be sped up, focusing on Europe.